Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease

Toxicology Letters

Volumn 222, Issue 2, 2013, Pages 155-163

  Zhang, Lingling ^b   Huang, LinHong ^b   Chen, Liangwei ^c   Hao, Dingjun ^b   Chen, Jianzong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Neuroprotection; Parkinson's disease; Phosphatidylinositol 3 kinase (PI3K) Akt; Tetrahydroxystilbene glucoside; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; CASPASE 9; NEUROPROTECTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; STILBENE DERIVATIVE; TETRAHYDROXYSTILBENE GLUCOSIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVATION; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PC12 CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

NEUROPROTECTION; PARKINSON'S DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE (PI3K)/AKT; TETRAHYDROXYSTILBENE GLUCOSIDE; TYROSINE HYDROXYLASE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; ATAXIA; BEHAVIOR, ANIMAL; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; GLUCOSIDES; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STILBENES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84882770585     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.07.020     Document Type: Article

References (77)

1. Amaravadi R., Thompson C.B. The survival kinases Akt and Pim as potential pharmacological targets. Journal of Clinical Investigation 2005, 115:2618-2624.
2. Avila J., Hernandez F. GSK-3 inhibitions for Alzheimer's disease. Expert Review of Neurotherapeutics 2007, 7:1527-1533.
3. Araki T., Hayashi M., Watanabe N., Kanuka H., Yoshino J., Miura M., Saruta T. Down-regulation of Mcl-1 by inhibition of the PI3-K/Akt pathway is required for cell shrinkage-dependent cell death. Biochemical and Biophysical Research Communications 2002, 290:1275-1281.
4. Betarbet R., Turner R., Chockkan V., DeLong M.R., Allers K.A., Walters J., Levey A.I., Greenamyre J.T. Dopaminergic neurons intrinsic to the primate striatum. Journal of Neuroscience 1997, 17:6761-6768.
5. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. BioEssays 2002, 24:308-318.
6. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β. Journal of Biological Chemistry 2001, 276:37436-37442.
7. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
8. Chalimoniuk M., Snoek G., Adamczyk A., Małecki A., Strosznajder J. Phosphatidylinositol transfer protein expression altered by aging and parkinson disease. Cellular and Molecular Neurobiology 2006, 26:1151-1164.
9. Chan Y.C., Cheng F.C., Wang M.F. Beneficial effects of different Polygonum multiflorum Thunb. Extracts on memory and hippocampus morphology. Journal of Nutritional Science and Vitaminology 2002, 48:491-497.
10. Chan Y.C., Wang M.F., Chang H.C. Polygonum multiflorum extracts improve cognitive performance in senescence accelerated mice. The American Journal of Chinese Medicine 2003, 31:171-179.
11. Cheng C.M., Reinhardt R.R., Lee W.-H., Joncas G., Patel S.C., Bondy C.A. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10236-10241.
12. Cohen P., Frame S. The renaissance of GSK3. Nature Reviews Molecular Cell Biology 2001, 2:769-776.
13. Cross D.A.E., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
14. Daftary S.S., Gore A.C. IGF-1 in the brain as a regulator of reproductive neuroendocrine function. Experimental Biology and Medicine 2005, 230:292-306.
15. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
16. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
17. D'Astous M., Mendez P., Morissette M., Garcia-Segura L.M., Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Molecular Pharmacology 2006, 69:1492-1498.
18. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. European Journal of Biochemistry 1980, 107:519-527.
19. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:11960-11965.
20. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
21. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego, CA.
22. Fukui M., Choi H.J., Zhu B.T. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radical Biology & Medicine 2010, 49:800-813.
23. Grünblatt E., Mandel S., Youdim M.B.H. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. Journal of Neurology 2000, 247:II95-II102.
24. Grütter M.G. Caspases: key players in programmed cell death. Current Opinion in Structural Biology 2000, 10:649-655.
25. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
26. Huang T.-J., Verkhratsky A., Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Molecular and Cellular Neuroscience 2005, 28:42-54.
27. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborsk S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
28. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007, 2:141-151.
29. Jakowec M.W., Nixon K., Hogg E., McNeill T., Petzinger G.M. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. Journal of Neuroscience Research 2004, 76:539-550.
30. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:2173-2177.
31. Jiang H., Guo W., Liang X., Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell 2005, 120:123-135.
32. Jope R.S., Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends in Biochemical Sciences 2004, 29:95-102.
33. Joyce J.N., Smutzer G., Whitty C.J., Myers A., Bannon M.J. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Movement Disorders 1997, 12:885-897.
34. +, specifically impairs mitochondrial transport in dopamine axons. Journal of Neuroscience 2011, 31:7212-7221.
35. Kopin I.J., Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Annual Review of Neuroscience 1988, 11:81-96.
36. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 1996, 47:153S-160S.
37. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
38. Levy O., Malagelada C., Greene L. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009, 14:478-500.
39. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
40. Li X., Matsumoto K., Murakami Y., Tezuka Y., Wu Y., Kadota S. Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice. Pharmacology Biochemistry and Behavior 2005, 82:345-352.
41. Li C., Cai F., Yang Y., Zhao X., Wang C., Li J., Jia Y., Tang J., liu Q. Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-β1 pathway. European Journal of Pharmacology 2010, 649:382-389.
42. Liu J.H., Yin F., Guo L.X., Deng X.H., Hu Y.H. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacologica Sinica 2009, 30:159-165.
43. Malagelada C., Jin Z.H., Greene L.A. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. Journal of Neuroscience 2008, 28:14363-14371.
44. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
45. Martinez A., Alonso M., Castro A., Pérez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3β (GSK3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry 2002, 45:1292-1299.
46. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. Journal of Neuroscience Methods 1997, 73:45-48.
47. Merry D.E., Korsmeyer S.J. Bcl-2 gene family in the nervous system. Annual Review of Neuroscience 1997, 20:245-267.
48. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annual Review of Neuroscience 2005, 28:57-87.
49. Mori A., Ohashi S., Nakai M., Moriizumi T., Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neuroscience Research 2005, 51:265-274.
50. Muyllaert D., Kremer A., Jaworski T., Borghgraef P., Devijver H., Croes S., Dewachter I., Van Leuven F. Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?. Genes, Brain and Behavior 2008, 7:57-66.
51. Nair V.D., Olanow C.W. Differential modulation of Akt/glycogen synthase kinase-3β pathway regulates apoptotic and cytoprotective signaling responses. Journal of Biological Chemistry 2008, 283:15469-15478.
52. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 1999, 22:123-144.
53. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. Journal of Biological Chemistry 1998, 273:19929-19932.
54. Peso L.d., González-García M., Page C., Herrera R., Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
55. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E.-B. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. Journal of Biological Chemistry 2000, 275:10761-10766.
56. +: the involvement of PI3K/Akt pathway activation. Toxicology Letters 2011, 202:1-7.
57. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18757-18762.
58. Ryu G., Ju J., Park Y., Ryu S., Choi B., Lee B. The radical scavenging effects of stilbene glucosides from Polygonum multiflorum. Archives of Pharmacal Research 2002, 25:636-639.
59. Ruan H., Yang Y., Zhu X., Wang X., Chen R. Neuroprotective effects of (±)catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice. Neuroscience Letters 2009, 450:152-157.
60. Sagi Y., Mandel S., Amit T., Youdim M.B.H. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiology of Disease 2007, 25:35-44.
61. Sedelis M., Schwarting R.K.W., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behavioural Brain Research 2001, 125:109-122.
62. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of Neurochemistry 1993, 61:1191-1206.
63. Timmons S., Coakley M.F., Moloney A.M., Neill C.O'. Akt signal transduction dysfunction in Parkinson's disease. Neuroscience Letters 2009, 467:30-35.
64. Toulouse A., Sullivan A.M. Progress in Parkinson's disease's-Where do we stand?. Progress in Neurobiology 2008, 85:376-392.
65. Um M.-Y., Choi W.-H., Aan J.-Y., Kim S.-R., Ha T.-Y. Protective effect of Polygonum multiflorum Thunb on amyloid β-peptide 25-35 induced cognitive deficits in mice. Journal of Ethnopharmacology 2006, 104:144-148.
66. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S.-i., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiology of Aging 2008, 29:574-585.
67. Wang W., Yang Y., Ying C., Li W., Ruan H., Zhu X., You Y., Han Y., Chen R., Wang Y., Li M. Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007, 52:1678-1684.
68. Wang X., Zhao L., Han T., Chen S., Wang J. Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. European Journal of Pharmacology 2008, 578:339-348.
69. Wang T., Gu J., Wu P.-F., Wang F., Xiong Z., Yang Y.-J., Wu W.-N., Dong L.-D., Chen J.-G. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radical Biology & Medicine 2009, 47:229-240.
70. Weinreb O., Mandel S., Bar-Am O., Yogev-Falach M., Avramovich-Tirosh Y., Amit T., Youdim M.B.H. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 2009, 6:163-174.
71. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends in Neurosciences 1999, 22:51-61.
72. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO Journal 1990, 9:2431-2438.
73. Wu W., Lee W.-L., Wu Y.Y., Chen D., Liu T.-J., Jang A., Sharma P.M., Wang P.H. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. Journal of Biological Chemistry 2000, 275:40113-40119.
74. Xiromerisiou G., Hadjigeorgiou G.M., Papadimitriou A., Katsarogiannis E., Gourbali V., Singleton A.B. Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neuroscience Letters 2008, 436:232-234.
75. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. BBA - Molecular Basis of Disease 2009, 1792:676-687.
76. Yao R., Cooper G. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995, 267:2003-2006.
77. Yu Y., Wang J.-R., Sun P.-H., Guo Y., Zhang Z.-J., Jin G.-Z., Zhen X. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3β and a receptor-independent anti-oxidative action. Journal of Neurochemistry 2008, 104:946-956.